Key result
GLP-1 receptor agonists improve lung function and boost ANP expression ~10-fold in COPD models.
Why the study?
GLP-1 is protective in lung disease models through unclear mechanisms, prompting investigation into whether its beneficial effects are mediated by ANP expression in COPD.
Does GLP-1 receptor agonism improve lung function via ANP expression in a female mouse model of COPD?
Does GLP-1 receptor agonism improve lung function via ANP expression in a female mouse model of COPD?
GLP-1 receptor agonism improves pulmonary function and reduces inflammation in a COPD mouse model, potentially mediated by increased ANP expression.
Glucagon-like peptide-1 (GLP-1) is protective in lung disease models but the underlying mechanisms remain elusive. Because the hormone atrial natriuretic peptide (ANP) also has beneficial effects in lung disease, we hypothesized that GLP-1 effects may be mediated by ANP expression. To study this putative link, we used a mouse model of chronic obstructive pulmonary disease (COPD) and assessed lung function by unrestrained whole-body plethysmography. In 1 study, we investigated the role of endogenous GLP-1 by genetic GLP-1 receptor (GLP-1R) knockout (KO) and pharmaceutical blockade of the GLP-1R with the antagonist exendin-9 to -39 (EX-9). In another study the effects of exogenous GLP-1 were assessed. Lastly, we investigated the bronchodilatory properties of ANP and a GLP-1R agonist on isolated bronchial sections from healthy and COPD mice. Lung function did not differ between mice receiving phosphate-buffered saline (PBS) and EX-9 or between GLP-1R KO mice and their wild-type littermates. The COPD mice receiving GLP-1R agonist improved pulmonary function (P < .01) with less inflammation, but no less emphysema compared to PBS-treated mice. Compared with the PBS-treated mice, treatment with GLP-1 agonist increased ANP (nppa) gene expression by 10-fold (P < .01) and decreased endothelin-1 (P < .01), a peptide associated with bronchoconstriction. ANP had moderate bronchodilatory effects in isolated bronchial sections and GLP-1R agonist also showed bronchodilatory properties but less than ANP. Responses to both peptides were significantly increased in COPD mice (P < .05, P < .01). Taken together, our study suggests a link between GLP-1 and ANP in COPD.
No takes yet. Share an insight, caveat, or question.
Balk-Møller et al. (2019) studied Chronic Obstructive Pulmonary Disease (COPD). Liraglutide (GLP-1R agonist) vs. Phosphate-buffered saline (PBS) was evaluated on Lung function (bronchoconstriction measured by enhanced pause [PenH]) (p=<0.01). Treatment with a GLP-1 receptor agonist significantly improved pulmonary function (P < 0.01) and increased atrial natriuretic peptide gene expression by 10-fold compared to placebo in a mouse model of COPD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: